Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine

European Journal of Clinical Pharmacology

Volumn 50, Issue 1-2, 1996, Pages 121-128

  Muralidharan, G ^a,c   Cooper, J K ^a   Hawes, E M ^a   Korchinski, E D ^a,b   Midha, K K ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c WYETH AYERST RESEARCH   (United States)

Author keywords

7 Hydroxychlorpromazine; Chlorpromazine; CYP2D6; Polymorphic metabolism; Quinidine

Indexed keywords

CHLORPROMAZINE; CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DRUG METABOLITE; QUINIDINE; QUINIDINE ACID SULFATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EXCRETION; DRUG HYDROXYLATION; DRUG INTERACTION; DRUG METABOLISM; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADULT; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEBRISOQUIN; DEPRESSION, CHEMICAL; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; MALE; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; PHENOTYPE; POLYMORPHISM, GENETIC; QUINIDINE;

EID: 0029926747     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050079     Document Type: Article

References (30)

1. Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzier-Perey M, Koeb L, Monney C, Woggon B (1992) Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit 14:1-8
2. Boobis AR, Edwards RJ, Singleton A, Sesardic D, Murray B, Speirs CJ, Murray S, Kobayashi S, Davies DS (1988) The contribution of polymorphic isozymes of cytochrome P-450 to the pharmacokinetics and toxicity of foreign compounds in man. In: Miners JO, Birkett DJ, Drew R, May BK, McManus ME (eds) Microsomes and drug oxidations. Proceedings of the 7th International Symposium. Taylor and Francis, London, pp 216-223
3. Brosen K (1990) Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics. Clin Pharmacokinet 18:220-239
4. Brøsen K, Gram LF (1989) Clinical signficance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36:537-547
5. Cashman JR, Yang Z, Yang L, Wrighton SA (1993) Stereo- and regioselective N- and S-oxidation of tertiary amines and sulfides in the presence of adult human liver microsomes. Drug Metab Dispos 21:492-501
6. 3H-Haloperidol binding to dopamine receptors in rat corpus striatum: influence of chlorpromazine metabolites and derivatives. Eur J Pharmacol 47:291-296
7. Dahl SG, Hall H (1981) Binding affinity of levomepromazine and two of its major metabolites to central dopamine and α-adrenergic receptors in the rat. Psychopharmacology 74:101-104
8. Dahl-Puustinen M-L, Lidén A, Aim C, Nordin C, Bertilsson L (1989) Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 46:78-81
9. Derenne F, Joanne C, Vandel S, Bertschy G, Volmat R, Bechtel P (1989) Debrisoquine oxidative phenotyping and psychiatric drug treatment. Eur J Clin Pharmacol 36:53-58
10. Eichelbaum M, Gross AS (1990) The genetic polymorphisms of debrisoquine/sparteine metabolism-clinical aspects. Pharmacol Ther 46:377-394
11. Fonne-Pfister R, Meyer UA (1988) Xenobiotic and endobiotic inhibitors of cytochrome P-450db1 function, the target of the debrisoquine/sparteine type polymorphism. Biochem Pharmacol 37:3829-3835
12. Islam SA, Wolf CR, Lennard MS, Sternberg MJE (1991) A three-dimensional molecular template for substrates of human cytochrome P450 in debrisoquine 4-hydroxylation. Carcinogenesis 12:2211-2219
13. Jørgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. Prog Drug Metab 9:111-174
14. Kallio J, Huupponen R, Seppälä M, Säkö E, Iisalo E (1990) The effects of β-adrenoceptor antagonists and levomepromazine on the metabolic ratio of debrisoquine. Br J Clin Pharmacol 30:638-643
15. Koymans L, Vermeulen NPE, van Acker SABE, te Koppele JM, Heykants JJP, Lavrijsen K, Meuldermans W, den Kelder GMD (1992) A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 5:211-219
16. Lledó P (1993) Variations in drug metabolism due to genetic polymorphism, a review of the debrisoquine/sparteine type. Drug Invest 5:19-34
17. Meyer JW, Woggon B, Baumann P, Meyer UA (1990) Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol 39:613-614
18. Midha KK, Loo JCK, Rowe ML (1979) The influence of blood sampling technique on the distribution of chlorpromazine and tricyclic antidepressants between plasma and whole blood. Res Commun Psychol Psychiatr Behav 4:193-203
19. Midha KK, Hubbard JW, Cooper JK, Gurnsey T, Hawes EM, McKay G, Chakraborty BS, Yeung PKF (1987) Therapeutic monitoring of chlorpromazine IV. Comparison of a new high-performance liquid chromatographic method with radioimmunoassays for parent drug and some of its major metabolites. Ther Drug Monit 9:358-365
20. Muralidharan G, Midha KK, McKay G, Hawes EM, Inaba T (1989) Selective in vivo inhibition by quinidine of methoxyphenamine oxidation in rat models of human debrisoquine polymorphism. Xenobiotica 19:189-197
21. Muralidharan G, Hawes EM, McKay G, Korchinski ED, Midha KK (1991) Quinidine but not quinine inhibits in man the oxidative metabolic routes of methoxyphenamine which involve debrisoquine 4-hydroxylase. Eur J Clin Pharmacol 41:471-474
22. Nielsen MD, Brøsen K, Gram LF (1990) A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br J Clin Pharmacol 29:299-304
23. Otton SV, Inaba T, Kalow W (1983) Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs. Life Sci 32:795-800
24. Roy SD, Hawes EM, McKay G, Korchinski ED, Midha KK (1985) Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquine. Clin Pharmacol Ther 38: 128-133
25. Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS (1986) Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol 22:739-743
26. Spina E, Martines C, Caputi AP, Cobaleda J, Piǹas B, Cariillo JA, Benitez J (1991) Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol 41:467-470
27. Syvälahti EKG, Lindberg R, Kallio J, de Vocht M (1986) Inhibitory effects of neuroleptics on debrisoquine oxidation in man. Br J Clin Pharmacol 22:89-92
28. von Bahr C, Spina E, Birgersson C, Ericsson Ö, Göransson M, Henthorn T, Sjöqvist F (1985) Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol 34:2501-2505
29. von Bahr C, Movin G, Nordin C, Lidén A, Hammarlund-Udenaes M, Hedberg A, Ring H, Sjöqvist F (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 49: 234-240
30. Yeung PK-F, Hubbard JW, Korchinski ED, Midha KK (1993) Pharmacokinetics of chlorpromazine and key metabolites. Eur J Clin Pharmacol 45:563-569